-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis - -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- .
03.01.2024 - -Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) - Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral .
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.